Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Holdings Decreased by State Street Corp

State Street Corp lowered its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 9.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 409,510 shares of the company’s stock after selling 44,300 shares during the quarter. State Street Corp’s holdings in Karyopharm Therapeutics were worth $340,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KPTI. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Karyopharm Therapeutics during the second quarter worth approximately $143,000. Acadian Asset Management LLC acquired a new stake in Karyopharm Therapeutics in the second quarter worth approximately $167,000. Exchange Traded Concepts LLC lifted its position in Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after purchasing an additional 56,613 shares during the period. Finally, FMR LLC increased its position in shares of Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares during the period. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Down 3.9 %

Shares of Karyopharm Therapeutics stock opened at $0.78 on Friday. Karyopharm Therapeutics Inc. has a 12-month low of $0.58 and a 12-month high of $1.95. The firm has a market capitalization of $98.42 million, a PE ratio of -0.68 and a beta of 0.05. The stock’s fifty day moving average is $0.78 and its 200-day moving average is $0.82.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. Analysts expect that Karyopharm Therapeutics Inc. will post -0.94 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on KPTI shares. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Piper Sandler upped their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).